Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 16 to 20 of 20 results for fulvestrant

  1. Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer (TA619)

    This guidance has been updated and replaced by NICE technology appraisal guidance 836.

    Technology appraisal guidance
    Published
    15 January 2020

  2. Abemaciclib with fulvestrant for previously treated hormone receptor-positive HER2-negative advanced breast cancer TSID 12065

    In development [GID-TA11588] Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Alpelisib with fulvestrant for treating hormone-receptor positive, HER2-negative, PIK3CA-positive advanced breast cancer (terminated appraisal) (TA652)

    This guidance has been updated and replaced by NICE technology appraisal guidance 816.

    Technology appraisal guidance
    Published
    7 October 2020

  4. NICE recommends 2 new breast cancer drugs

    NICE recommends Piqray and Trodelvy, maintaining 100% approvals of breast cancer drugs since 2018.

    News
    Last updated
    13 June 2024

  5. NICE approves routine use of drug combination for advanced breast cancer

    A life-extending drug combination for some people with advanced breast cancer will now be available for routine use in the NHS.

    News
    Last updated
    18 January 2024